NON-MUSCLE INVASIVE BLADDER CANCER
Pioneering a novel approach to treat a high unmet medical need.
Bladder cancer is the most common malignancy involving the urinary system and approximately 84,000 Americans will be diagnosed with bladder cancer in 2021. An estimated 70% of all new primary bladder cancer cases are classified as non-muscle invasive bladder cancer, or NMIBC. NMIBC occurs in the tissue that lines the inner surface of the bladder and where the bladder muscle is not involved. NMIBC is currently treated with a combination of surgery, immunotherapy, and chemotherapy, and there have been no new advances in the treatment of NMIBC in over two decades.